Lonnel Coats, Lexicon CEO

De­sert­ed by Sanofi, Lex­i­con dis­clos­es last-minute hic­cup in its so­lo fight to get so­tagliflozin ap­proved

When the FDA first snubbed Sanofi and Lex­i­con’s NDA for so­tagliflozin back in 2019, the re­jec­tion quashed their hopes of scor­ing a last-place fin­ish in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.